公开(公告)号：US20120039874A1

公开(公告)日：2012-02-16

申请号：US13166288

申请日：2011-06-22

申请人： Takashi Tsuji ,  Katsunari Tezuka ,  Nobuaki Hori

发明人： Takashi Tsuji ,  Katsunari Tezuka ,  Nobuaki Hori

IPC分类号： A61K39/395 ,  A61P3/10 ,  A61P37/06 ,  A61P29/00 ,  A61P17/06

CPC分类号： C07K16/18 ,  A01K2217/05 ,  A61K2039/505 ,  C07K16/28 ,  C07K16/2818 ,  C07K2317/21 ,  C07K2317/56 ,  C07K2317/73 ,  C07K2317/732 ,  C07K2317/76 ,  C07K2317/92 ,  C07K2319/00 ,  C07K2319/30

摘要： Immunization of human antibody-producing transgenic mice, which have been created using genetic engineering techniques, with AILIM molecule as an antigen resulted in various human monoclonal antibodies capable of binding to AILIM and capable of controlling a variety of biological reactions (for example, cell proliferation, cytokine production, immune cytolysis, cell death, induction of ADCC, etc.) associated with AILIM-mediated costimulatory signal (secondary signal) transduction. Furthermore, it has been revealed that the human monoclonal antibody is effective to treat and prevent various diseases associated with AILIM-mediated costimulatory signal transduction, being capable of inhibiting the onset and/or advancement of the diseases.

摘要翻译： 用AILIM分子作为抗原，使用基因工程技术产生的产生抗体的转基因小鼠的免疫导致能够结合AILIM并能够控制多种生物反应的各种人单克隆抗体（例如，细胞增殖 ，细胞因子产生，免疫细胞溶解，细胞死亡，诱导ADCC等）与AILIM介导的共刺激信号（二级信号）转导相关。 此外，已经揭示了人单克隆抗体有效治疗和预防与AILIM介导的共刺激信号转导相关的各种疾病，能够抑制疾病的发病和/或进展。

公开(公告)号：US20080199466A1

公开(公告)日：2008-08-21

申请号：US11752659

申请日：2007-05-23

申请人： Takashi Tsuji ,  Katsunari Tezuka ,  Nobuaki Hori

发明人： Takashi Tsuji ,  Katsunari Tezuka ,  Nobuaki Hori

IPC分类号： A61K39/395 ,  C07K16/18 ,  C07H21/04 ,  C12N15/00 ,  G01N33/566 ,  A61K31/7088 ,  C12N5/00 ,  C12N5/06

CPC分类号： C07K16/18 ,  A01K2217/05 ,  A61K2039/505 ,  C07K16/28 ,  C07K16/2818 ,  C07K2317/21 ,  C07K2317/56 ,  C07K2317/73 ,  C07K2317/732 ,  C07K2317/76 ,  C07K2317/92 ,  C07K2319/00 ,  C07K2319/30

摘要： Immunization of human antibody-producing transgenic mice, which have been created using genetic engineering techniques, with AILIM molecule as an antigen resulted in various human monoclonal antibodies capable of binding to AILIM and capable of controlling a variety of biological reactions (for example, cell proliferation, cytokine production, immune cytolysis, cell death, induction of ADCC, etc.) associated with AILIM-mediated costimulatory signal (secondary signal) transduction. Furthermore, it has been revealed that the human monoclonal antibody is effective to treat and prevent various diseases associated with AILIM-mediated costimulatory signal transduction, being capable of inhibiting the onset and/or advancement of the diseases.

摘要翻译： 用AILIM分子作为抗原，使用基因工程技术产生的产生抗体的转基因小鼠的免疫导致能够结合AILIM并能够控制多种生物反应的各种人单克隆抗体（例如，细胞增殖 ，细胞因子产生，免疫细胞溶解，细胞死亡，诱导ADCC等）与AILIM介导的共刺激信号（二级信号）转导相关。 此外，已经揭示了人单克隆抗体有效治疗和预防与AILIM介导的共刺激信号转导相关的各种疾病，能够抑制疾病的发病和/或进展。

公开(公告)号：US07166283B2

公开(公告)日：2007-01-23

申请号：US10625105

申请日：2003-07-22

申请人： Takashi Tsuji ,  Katsunari Tezuka ,  Nobuaki Hori

发明人： Takashi Tsuji ,  Katsunari Tezuka ,  Nobuaki Hori

IPC分类号： A61K39/395 ,  C07K16/00

CPC分类号： C07K16/18 ,  A01K2217/05 ,  A61K2039/505 ,  C07K16/28 ,  C07K16/2818 ,  C07K2317/21 ,  C07K2317/56 ,  C07K2317/73 ,  C07K2317/732 ,  C07K2317/76 ,  C07K2317/92 ,  C07K2319/00 ,  C07K2319/30

摘要： Immunization of human antibody-producing transgenic mice, which have been created using genetic engineering techniques, with AILIM molecule as an antigen resulted in various human monoclonal antibodies capable of binding to AILIM and capable of controlling a variety of biological reactions (for example, cell proliferation, cytokine production, immune cytolysis, cell death, induction of ADCC, etc.) associated with AILIM-mediated costimulatory signal (secondary signal) transduction. Furthermore, it has been revealed that the human monoclonal antibody is effective to treat and prevent various diseases associated with AILIM-mediated costimulatory signal transduction, being capable of inhibiting the onset and/or advancement of the diseases.

摘要翻译： 用AILIM分子作为抗原，使用基因工程技术产生的产生抗体的转基因小鼠的免疫导致能够结合AILIM并能够控制多种生物反应的各种人单克隆抗体（例如，细胞增殖 ，细胞因子产生，免疫细胞溶解，细胞死亡，诱导ADCC等）与AILIM介导的共刺激信号（二级信号）转导相关。 此外，已经揭示了人单克隆抗体有效治疗和预防与AILIM介导的共刺激信号转导相关的各种疾病，能够抑制疾病的发病和/或进展。

公开(公告)号：US07988965B2

公开(公告)日：2011-08-02

申请号：US11752659

申请日：2007-05-23

申请人： Takashi Tsuji ,  Katsunari Tezuka ,  Nobuaki Hori

发明人： Takashi Tsuji ,  Katsunari Tezuka ,  Nobuaki Hori

IPC分类号： A61K39/395

CPC分类号： C07K16/18 ,  A01K2217/05 ,  A61K2039/505 ,  C07K16/28 ,  C07K16/2818 ,  C07K2317/21 ,  C07K2317/56 ,  C07K2317/73 ,  C07K2317/732 ,  C07K2317/76 ,  C07K2317/92 ,  C07K2319/00 ,  C07K2319/30

摘要： Immunization of human antibody-producing transgenic mice, which have been created using genetic engineering techniques, with AILIM molecule as an antigen resulted in various human monoclonal antibodies capable of binding to AILIM and capable of controlling a variety of biological reactions (for example, cell proliferation, cytokine production, immune cytolysis, cell death, induction of ADCC, etc.) associated with AILIM-mediated costimulatory signal (secondary signal) transduction. Furthermore, it has been revealed that the human monoclonal antibody is effective to treat and prevent various diseases associated with AILIM-mediated costimulatory signal transduction, being capable of inhibiting the onset and/or advancement of the diseases.

摘要翻译： 用AILIM分子作为抗原，使用基因工程技术产生的产生抗体的转基因小鼠的免疫导致能够结合AILIM并能够控制多种生物反应的各种人单克隆抗体（例如，细胞增殖 ，细胞因子产生，免疫细胞溶解，细胞死亡，诱导ADCC等）与AILIM介导的共刺激信号（二级信号）转导相关。 此外，已经揭示了人单克隆抗体有效治疗和预防与AILIM介导的共刺激信号转导相关的各种疾病，能够抑制疾病的发病和/或进展。

公开(公告)号：US06803039B2

公开(公告)日：2004-10-12

申请号：US09859053

申请日：2001-05-16

申请人： Takashi Tsuji ,  Katsunari Tezuka ,  Nobuaki Hori

发明人： Takashi Tsuji ,  Katsunari Tezuka ,  Nobuaki Hori

IPC分类号： A61K39395

CPC分类号： C07K16/18 ,  A01K2217/05 ,  A61K2039/505 ,  C07K16/28 ,  C07K16/2818 ,  C07K2317/21 ,  C07K2317/56 ,  C07K2317/73 ,  C07K2317/732 ,  C07K2317/76 ,  C07K2317/92 ,  C07K2319/00 ,  C07K2319/30

摘要： Immunization of human antibody-producing transgenic mice, which have been created using genetic engineering techniques, with AILIM molecule as an antigen resulted in various human monoclonal antibodies capable of binding to AILIM and capable of controlling a variety of biological reactions (for example, cell proliferation, cytokine production, immune cytolysis, cell death, induction of ADCC, etc.) associated with AILIM-mediated costimulatory signal (secondary signal) transduction. Furthermore, it has been revealed that the human monoclonal antibody is effective to treat and prevent various diseases associated with AILIM-mediated costimulatory signal transduction, being capable of inhibiting the onset and/or advancement of the diseases.

摘要翻译： 用AILIM分子作为抗原，使用基因工程技术产生的产生抗体的转基因小鼠的免疫导致能够结合AILIM并能够控制多种生物反应的各种人单克隆抗体（例如，细胞增殖 ，细胞因子产生，免疫细胞溶解，细胞死亡，诱导ADCC等）与AILIM介导的共刺激信号（二级信号）转导相关。 此外，已经揭示了人单克隆抗体有效治疗和预防与AILIM介导的共刺激信号转导相关的各种疾病，能够抑制疾病的发病和/或进展。

公开(公告)号：US08765669B2

公开(公告)日：2014-07-01

申请号：US12999654

申请日：2009-06-15

申请人： Yasuhiro Kajihara ,  Takashi Tsuji ,  Izumi Sakamoto ,  Yuri Nambu ,  Naohiro Hayashi ,  Kazuyuki Ishii ,  Kazuhiro Fukae ,  Katsunari Tezuka ,  Hiroaki Asai

发明人： Yasuhiro Kajihara ,  Takashi Tsuji ,  Izumi Sakamoto ,  Yuri Nambu ,  Naohiro Hayashi ,  Kazuyuki Ishii ,  Kazuhiro Fukae ,  Katsunari Tezuka ,  Hiroaki Asai

IPC分类号： A61K38/26 ,  A61P3/10 ,  A61P7/12 ,  C07K14/605 ,  C07K1/00 ,  C07K14/00 ,  C07K17/00

CPC分类号： C07K14/605 ,  A61K38/00

摘要： Oligosaccharide chain added GLP-1 peptides are more stable in blood and more active in controlling blood-sugar levels than GLP-1 peptides without added oligosaccharides. Oligosaccharide chain added GLP-1 peptides having GLP-1 activity include at least one or at least two amino acids each substituted with an oligosaccharide chain added amino acid in GLP-1; a peptide having the amino acid sequence of GLP-1 with deletion, substitution or addition of one or several amino acids; or a GLP-1 analog. Oligosaccharide chain added GLP-1 peptides with at least one amino acid substituted with an oligosaccharide chain added amino acid include an oligosaccharide chain with oligo hyaluronic acid. Oligosaccharide chain added amino acids include oligosaccharide chains attached to amino acids via linkers.

摘要翻译： 添加糖链的GLP-1肽在血液中更稳定，并且在没有添加低聚糖的情况下比GLP-1肽更有效地控制血糖水平。 具有GLP-1活性的添加糖链的GLP-1肽包括GLP-1中由糖链连接的氨基酸取代的至少一个或至少两个氨基酸; 具有GLP-1的氨基酸序列的肽，其具有缺失，取代或添加一个或几个氨基酸; 或GLP-1类似物。 具有至少一个被寡糖链添加的氨基酸取代的氨基酸的添加糖链的GLP-1肽包括具有寡聚透明质酸的寡糖链。 寡糖链添加的氨基酸包括通过接头连接到氨基酸的寡糖链。

公开(公告)号：US20120047586A9

公开(公告)日：2012-02-23

申请号：US12739480

申请日：2008-10-23

申请人： Takashi Tsuji ,  Yasuhiro Kajihara ,  Katsunari Tezuka ,  Yuri Nambu ,  Kazuhiro Fukae ,  Hiroaki Asai

发明人： Takashi Tsuji ,  Yasuhiro Kajihara ,  Katsunari Tezuka ,  Yuri Nambu ,  Kazuhiro Fukae ,  Hiroaki Asai

IPC分类号： C12P21/02 ,  C07H21/04 ,  A01H5/00 ,  C12N5/10 ,  A01K67/00 ,  C07K16/28 ,  C12N15/63

CPC分类号： C07K16/00 ,  A61K38/00 ,  C07K16/2887 ,  C07K2317/72 ,  C07K2317/732 ,  C07K2319/30 ,  C07K2319/33

摘要： Disclosed is a polypeptide having an enhanced effector function. Specifically disclosed are: a polypeptide having a modified Fc region; a nucleic acid encoding the polypeptide; a vector carrying the nucleic acid; a host cell or a host organism harboring the vector; a pharmaceutical composition comprising the polypeptide; a method for producing the polypeptide; a method for enhancing the effector function of an antibody; and a method for producing a cell capable of producing an antibody having a high effector function.

摘要翻译： 公开了具有增强的效应子功能的多肽。 具体公开的是：具有修饰的Fc区的多肽; 编码该多肽的核酸; 携带核酸的载体; 携带载体的宿主细胞或宿主生物体; 包含该多肽的药物组合物; 一种生产该多肽的方法; 用于增强抗体的效应子功能的方法; 以及能够产生具有高效应功能的抗体的细胞的制备方法。

公开(公告)号：US20120264684A1

公开(公告)日：2012-10-18

申请号：US13502723

申请日：2010-10-25

申请人： Yasuhiro Kajihara ,  Takashi Tsuji ,  Yuri Nambu ,  Kazuyuki Ishii ,  Kenta Yoshida ,  Katsunari Tezuka

发明人： Yasuhiro Kajihara ,  Takashi Tsuji ,  Yuri Nambu ,  Kazuyuki Ishii ,  Kenta Yoshida ,  Katsunari Tezuka

IPC分类号： C07K14/605 ,  A61P3/10 ,  A61K38/26

CPC分类号： C07K14/605 ,  A61K38/00

摘要： Disclosed is a glucagon-like peptide-1 (GLP-1) analogue which is obtained by ameliorating a highly antigenic GLP-1 analogue so that the GLP-1 analogue has reduced antigenicity without being lowered in the blood glucose suppressing activity. Specifically disclosed is a glycosylated form of an antigenic GLP-1 analogue, which has GLP-1 activity and is obtained by substituting at least one amino acid of an antigenic GLP-1 analogue with a glycosylated amino acid.

摘要翻译： 公开了通过改善高度抗原性GLP-1类似物而获得的胰高血糖素样肽-1（GLP-1）类似物，使得GLP-1类似物具有降低的抗原性而不降低血糖抑制活性。 具体公开的是具有GLP-1活性的抗原性GLP-1类似物的糖基化形式，其通过用糖基化氨基酸取代抗原性GLP-1类似物的至少一个氨基酸获得。

公开(公告)号：US20100306864A1

公开(公告)日：2010-12-02

申请号：US12739480

申请日：2008-10-23

申请人： Takashi Tsuji ,  Yasuhiro Kajihara ,  Katsunari Tezuka ,  Yuri Nambu ,  Kazuhiro Fukae ,  Hiroaki Asai

发明人： Takashi Tsuji ,  Yasuhiro Kajihara ,  Katsunari Tezuka ,  Yuri Nambu ,  Kazuhiro Fukae ,  Hiroaki Asai

IPC分类号： C12P21/02 ,  C07K16/28 ,  C07H21/04 ,  C12N15/63 ,  C12N5/10 ,  A01K67/00 ,  A01H5/00

CPC分类号： C07K16/00 ,  A61K38/00 ,  C07K16/2887 ,  C07K2317/72 ,  C07K2317/732 ,  C07K2319/30 ,  C07K2319/33

摘要： Disclosed is a polypeptide having an enhanced effector function. Specifically disclosed are: a polypeptide having a modified Fc region; a nucleic acid encoding the polypeptide; a vector carrying the nucleic acid; a host cell or a host organism harboring the vector; a pharmaceutical composition comprising the polypeptide; a method for producing the polypeptide; a method for enhancing the effector function of an antibody; and a method for producing a cell capable of producing an antibody having a high effector function.

摘要翻译： 公开了具有增强的效应子功能的多肽。 具体公开的是：具有修饰的Fc区的多肽; 编码该多肽的核酸; 携带核酸的载体; 携带载体的宿主细胞或宿主生物体; 包含该多肽的药物组合物; 一种生产该多肽的方法; 用于增强抗体的效应子功能的方法; 以及能够产生具有高效应功能的抗体的细胞的制备方法。

公开(公告)号：US08507429B2

公开(公告)日：2013-08-13

申请号：US13152082

申请日：2011-06-02

申请人： Yasuhiro Kajihara ,  Takashi Tsuji ,  Izumi Sakamoto ,  Yuri Nambu ,  Kazuhiro Fukae ,  Katsunari Tezuka ,  Hiroaki Asai

发明人： Yasuhiro Kajihara ,  Takashi Tsuji ,  Izumi Sakamoto ,  Yuri Nambu ,  Kazuhiro Fukae ,  Katsunari Tezuka ,  Hiroaki Asai

IPC分类号： A61K38/26 ,  A61K38/14

CPC分类号： C07K14/605 ,  A61K38/00

摘要： The present invention relates to an oligosaccharide chain added GLP-1 peptide that has higher stability in blood than that of GLP-1 and, preferably, exhibits higher activity of controlling blood-sugar levels than that of GLP-1. The present invention relates to an oligosaccharide chain added GLP-1 peptide having GLP-1 activity, wherein at least one amino acid is substituted with an oligosaccharide chain added amino acid, in: (a) GLP-1; (b) a peptide having the amino acid sequence of GLP-1 with deletion, substitution or addition of one or several amino acids; or (c) a GLP-1 analog.

摘要翻译： 本发明涉及一种与GLP-1相比血液中稳定性更高的糖链附加GLP-1肽，优选表现出比GLP-1更高的控制血糖水平的活性。 本发明涉及：（a）GLP-1;具有GLP-1活性的附加了糖链的GLP-1肽，其中至少一个氨基酸被添加了糖链的氨基酸取代。 （b）具有缺失，取代或添加一个或几个氨基酸的具有GLP-1氨基酸序列的肽; 或（c）GLP-1类似物。